School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia.
Department of Pharmacy, Jambi Regional Psychiatric Hospital, Jambi, 36129, Indonesia.
BMC Womens Health. 2021 Oct 4;21(1):348. doi: 10.1186/s12905-021-01478-z.
While women are taking a greater role in decisions about menopause symptom management, the legacy of the Women's Health Initiative (WHI) studies persist. Despite hormone therapy (HT) being effective in reducing all-cause mortality, many women seeking relief of menopausal symptoms exaggerate HT harms and overstate the perceived benefits or ignore the risks of alternative therapies. We aimed to explore the longitudinal impact of the widely-publicised WHI 2002 study on women's information-seeking and describe determinants of decision-making about managing menopausal symptoms.
In a longitudinal analysis of both quantitative and qualitative data, we explored consumer questions about menopause-related medicines received by two Australian medicines call centres (1996-2010) before, during, and after WHI 2002. We analysed calls by age and gender of caller and patient, their relationship, postcode, enquiry type, and motivation to help-seek. We compared calls regarding HT and herbal medicines (HM) with the rest of calls, and thematically analysed question narratives across the three time-periods.
There were 1,829 menopause-related calls received of over this time-period, with a call surge, primarily from women in their mid-fifties, in the two months after the WHI 2002 publication. Two in three calls were motivated by negative media reports as women sought support for decision-making, primarily reassurance to cease HT. While HT safety concerns persisted for eight years post-publication, the nature of information-seeking changed over time. Callers subsequently sought reassurance to use menopause treatments together with their other medicines; and pursued HT substitutes, including HM, in response to HT product discontinuation.
Women sought information or reassurance to support a decision, based on dynamic changes in internal (symptom or risk intolerance, attitude towards menopause and treatment preferences) and external factors (perceived source trust and changes in treatment availability). In assessing HT benefit versus risk, women tend to overestimate risk with HT safety concerns persisting over time. Decision-making in managing menopause symptoms is complex and dynamic. Reassurance to reach or justify decisions from a perceived trusted source can support informed decision-making.
尽管激素疗法(HT)在降低全因死亡率方面有效,但许多寻求缓解更年期症状的女性夸大了 HT 的危害,夸大了其感知益处,或忽视了替代疗法的风险。我们旨在探讨广泛宣传的妇女健康倡议(WHI)2002 年研究对女性信息寻求的纵向影响,并描述管理更年期症状决策的决定因素。
在对定量和定性数据的纵向分析中,我们探讨了两个澳大利亚药品呼叫中心(1996-2010 年)在 WHI 2002 年前后收到的与更年期相关药物的消费者询问。我们按来电者和患者的年龄和性别、他们的关系、邮政编码、询问类型和寻求帮助的动机对来电进行了分析。我们比较了关于 HT 和草药(HM)的来电与其余来电,并在三个时间段内对问题叙述进行了主题分析。
在此期间共收到 1829 个与更年期相关的来电,在 WHI 2002 年发表后的两个月内,来电激增,主要来自 50 多岁的女性。三分之二的来电是由负面媒体报道引发的,因为女性寻求决策支持,主要是为了停止 HT。尽管 HT 安全性问题在发布后持续了八年,但信息寻求的性质随着时间的推移而发生了变化。来电者随后寻求使用更年期治疗方法与其他药物一起使用的保证;并且在 HT 产品停止使用后,他们寻求 HT 替代品,包括 HM。
女性根据内部(症状或风险不耐受、对更年期和治疗偏好的态度)和外部因素(感知来源信任和治疗方法的变化)的动态变化寻求信息或保证以支持决策。在评估 HT 的益处与风险时,女性往往会高估风险,并且对 HT 安全性的担忧会随着时间的推移而持续存在。管理更年期症状的决策是复杂和动态的。从感知到的可信赖来源获得或证明决策的保证,可以支持做出明智的决策。